Molgramostim is a Recombinant Protein owned by Savara, and is involved in 6 clinical trials, of which 4 were completed, and 2 are ongoing.
Molgramostim activates GM-CSF receptor. It binds to specific cell surface receptors, modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function and it also augment host anti-tumoral immunity.
The revenue for Molgramostim is expected to reach a total of $1.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Molgramostim NPV Report.
Molgramostim is currently owned by Savara.
Molgramostim (Molgradex) is under development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), acute respiratory distress syndrome, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and non-tuberculous Mycobacteria (NTM) lung infections. It is administered via inhalational route as a solution. Molgramostim is a recombinant human granulocyte macrophage colony stimulating factor (GM-CSF). The drug candidate acts by targeting granulocyte macrophage colony-stimulating factor (GM-CSF) receptor. The drug development is developed based on veltis technology. It was also under development for the treatment of cystic fibrosis-related lung infection (CF), bronchiectasis (BE) and ventilator-associated pneumonia (VAP).
Savara, formerly Mast Therapeutics Inc, is a clinical-stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of PAP; and AeroVanc, an inhaled formulation of vancomycin for the treatment of CF. The company has subsidiaries in the US, and Denmark. Savara is headquartered in Austin, Texas, the US.
The operating loss of the company was US$41.5 million in FY2021, compared to an operating loss of US$49.3 million in FY2020. The net loss of the company was US$43 million in FY2021, compared to a net loss of US$49.6 million in FY2020.
Quick View – Molgramostim
|Highest Development Stage|